Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Investments (2016 - 2021)

Lifecore Biomedical, Inc. \De\ has reported Long-Term Investments over the past 11 years, most recently at $44.8 million for Q2 2021.

  • Quarterly results put Long-Term Investments at $44.8 million for Q2 2021, down 21.32% from a year ago — trailing twelve months through May 2021 was $44.8 million (down 21.32% YoY), and the annual figure for FY2021 was $44.8 million, down 21.32%.
  • Long-Term Investments for Q2 2021 was $44.8 million at Lifecore Biomedical, Inc. \De\, down from $45.1 million in the prior quarter.
  • Over the last five years, Long-Term Investments for LFCR hit a ceiling of $68.1 million in Q4 2018 and a floor of $44.8 million in Q2 2021.
  • Median Long-Term Investments over the past 5 years was $62.4 million (2017), compared with a mean of $60.3 million.
  • Biggest five-year swings in Long-Term Investments: rose 4.94% in 2017 and later decreased 26.43% in 2020.
  • Lifecore Biomedical, Inc. \De\'s Long-Term Investments stood at $65.8 million in 2017, then increased by 3.5% to $68.1 million in 2018, then dropped by 9.99% to $61.3 million in 2019, then decreased by 26.43% to $45.1 million in 2020, then dropped by 0.73% to $44.8 million in 2021.
  • The last three reported values for Long-Term Investments were $44.8 million (Q2 2021), $45.1 million (Q1 2021), and $45.1 million (Q4 2020) per Business Quant data.